
## Sean A Fletcher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1565284/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Using Competing Risk of Mortality to Inform the Transition from Prostate Cancer Active Surveillance to Watchful Waiting. European Urology Focus, 2022, 8, 1141-1150.	3.1	1
2	Race, ethnicity, and gender reporting in North American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 195.e13-195.e18.	1.6	6
3	On the Black–White Disparity in Prostate Cancer Mortality. JNCI Cancer Spectrum, 2022, 6, pkab094.	2.9	Ο
4	Workplace absenteeism amongst patients undergoing open vs. robotic radical prostatectomy, hysterectomy, and partial colectomy. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 1644-1650.	2.4	2
5	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 130.e17-130.e24.	1.6	4
6	What Diversity Means. Urology, 2021, , .	1.0	0
7	Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer and Prostatic Diseases, 2020, 23, 81-87.	3.9	39
8	The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65Âyears. Cancer, 2020, 126, 496-505.	4.1	19
9	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. JAMA Network Open, 2020, 3, e201839.	5.9	37
10	Recommended Cancer Screening in Accountable Care Organizations: Trends in Colonoscopy and Mammography in the Medicare Shared Savings Program. Journal of Oncology Practice, 2019, 15, e547-e559.	2.5	8
11	Multiparametric magnetic resonance imaging for prostate cancer detection: do clinical trial findings reflect realâ€world practice?. BJU International, 2019, 123, 197-198.	2.5	2
12	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. Clinical Genitourinary Cancer, 2019, 17, e488-e493.	1.9	11
13	Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer?. Prostate Cancer and Prostatic Diseases, 2019, 22, 593-599.	3.9	8
14	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. European Urology Oncology, 2019, 2, 349-354.	5.4	6
15	Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer. Prostate Cancer and Prostatic Diseases, 2019, 22, 125-136.	3.9	53
16	Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status. Annals of Surgical Oncology, 2019, 26, 297-305.	1.5	20
17	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscleâ€invasive carcinoma of the bladder: Does histologic subtype matter?. Cancer, 2019, 125, 1449-1458.	4.1	56
18	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome raceâ€based differences in survival?. Cancer, 2019, 125, 1319-1329.	4.1	20

SEAN A FLETCHER

#	Article	IF	CITATIONS
19	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. Journal of Urology, 2019, 201, 735-741.	0.4	31
20	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 238.e7-238.e17.	1.6	21
21	Adoption of robotic surgery: driven by market competition or a desire to improve patient care?. Lancet Oncology, The, 2018, 19, e66.	10.7	2
22	The new frontier of prostate biopsy: determining the role of imageâ€guidance in moving the needle. BJU International, 2018, 121, 4-5.	2.5	0
23	Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 400.e15-400.e22.	1.6	1
24	Use of Preventive Health Services Among Cancer Survivors in the U.S American Journal of Preventive Medicine, 2018, 55, 830-838.	3.0	11
25	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. World Journal of Urology, 2018, 36, 1767-1774.	2.2	12
26	Immortalâ€time bias: a crucial yet overlooked confounder in urological research. BJU International, 2017, 120, 455-455.	2.5	1
27	Barriers to Quality End-of-Life Care for Patients With Blood Cancers. Journal of Clinical Oncology, 2016, 34, 3126-3132.	1.6	108